Prevention of intrahepatic distant recurrence by transcatheter arterial infusion chemotherapy with platinum agents for stage I/II hepatocellular carcinoma
✍ Scribed by Toru Ishikawa; Kazuo Higuchi; Tomoyuki Kubota; Keiichi Seki; Terasu Honma; Toshiaki Yoshida; Tomoteru Kamimura
- Publisher
- John Wiley and Sons
- Year
- 2011
- Tongue
- English
- Weight
- 160 KB
- Volume
- 117
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
BACKGROUND:
The effectiveness of additional chemotherapy in preventing intrahepatic distant tumor recurrence of hepatocellular carcinoma (HCC) has not been fully established. The authors compared the efficacy of 2 platinum‐based chemotherapeutic agents in combination with radical local treatment for preventing intrahepatic distant recurrence (IDR).
METHODS:
Seventy‐eight patients with stage I/II HCC aged 45 to 85 years underwent transcatheter arterial chemoembolization and/or radiofrequency ablation after they received hepatic arterial infusion (HAI) of platinum compounds. The HAI consisted of cis‐diammine(1,1‐cyclobutanedicarboxylato)platinum(II) (carboplatin) in 25 patients and cis‐diamminedichloroplatinum (II) (cisplatin) in 53 patients. Multivariate analysis was used to identify independent factors that were associated with IDR.
RESULTS:
Cumulative IDR rates at 1 year, 2 years, and 3 years were 21.7%, 52.2% and 75.7%, respectively, in the carboplatin group and 8.1%, 22.7%, and 36.9%, respectively, in the cisplatin group. The cisplatin group had a significantly lower IDR rate compared with the carboplatin group. The selection of a platinum agent was 1 of the independent factors for IDR in a multivariate Cox proportional hazards model.
CONCLUSIONS:
HAI chemotherapy with cisplatin before radical local treatment was effective in patients with HCC. The authors concluded that radical local treatment with concurrent HAI using cisplatin may contribute to a longer progression‐free period, which could be predicted with intrahepatic imaging in patients with stage I/II HCC. Cancer 2011;. © 2011 American Cancer Society.